MCPH1 Protein Expression in Normal and Neoplastic Lung Tissues

  • Zhang, Ji (Molecular Medicine & Cancer Research Center) ;
  • Wu, Xiao-Bin (Molecular Medicine & Cancer Research Center) ;
  • Fan, Jian-Jun (Molecular Medicine & Cancer Research Center) ;
  • Mai, Li (Molecular Medicine & Cancer Research Center) ;
  • Cai, Wei (Department of Pathology of the First Affiliated Hospital of Chongqing Medical University) ;
  • Li, Dan (Department of Pathology of the First Affiliated Hospital of Chongqing Medical University) ;
  • Yuan, Cheng-Fu (Molecular Medicine & Cancer Research Center) ;
  • Bu, You-Quan (Department of Biochemistry & Molecular Biology, College of Basic Medicine, Chongqing Medical University) ;
  • Song, Fang-Zhou (Department of Biochemistry & Molecular Biology, College of Basic Medicine, Chongqing Medical University)
  • Published : 2013.12.31


Lung cancer is the most common cause of cancer-related death in the world. The main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), the latter including squamous cell carcinoma (SCC), adenocarcinoma and large cell carcinoma. NSCLCs account for about 80% of all lung cancer cases. Microcephalin (MCPH1), also called BRIT1 (BRCT-repeat inhibitor of hTERT expression), plays an important role in the maintenance of genomic stability. Recently, several studies have provided evidence that the expression of MCPH1 gene is decreased in several different types of human cancers. We evaluated the expression of protein MCPH1 in 188 lung cancer and 20 normal lung tissues by immunohistochemistry. Positive MCPH1 staining was found in all normal lung samples and only some cancerous tissues. MCPH1-positive cells were significantly lower in lung carcinoma compared with normal tissues. Furthermore, we firstly found that MCPH1 expression in lung adenocarcinoma is higher than its expression in squamous cell carcinoma. Change in MCPH1 protein expression may be associated with lung tumorigenesis and may be a useful biomarker for identification of pathological types of lung cancer.


  1. Farmer H, McCabe N, Lord C J, et al (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-21.
  2. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008, GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  3. Fossella F, Pereira JR, von Pawel J, et al (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer, The TAX 326 study group. Jf ClinOncol, 21, 3016-24, .
  4. Gavvovidis I, Rost I, Trimborn M, et al (2012). A novel MCPH1 isoform complements the defective chromosome condensation of human MCPH1-deficient cells. PLoS One, 7, e40387.
  5. Giallongo C, Tibullo D, La Cava P, et al (2011). BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. Acta Haematol, 126, 205-10.
  6. Giovino GA, Mirza SA, Samet JM, et al (2012). Tobacco use in 3 billion individuals from 16 countries, an analysisof nationally representative cross-sectionalhousehold surveys. Lancet, 380, 668-79.
  7. Goldberg M, Stucki M, Falck J, et al (2003). MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature, 421, 952-6.
  8. He J, Chen WQ (2013). Chinese Cancer Registry Annual Report In 2012. Military Medical Science Press, Beijing, China, C33-4.
  9. Hosseini MM, Tonekaboni SH, Papari E, et al (2012). A novel mutation in MCPH1 gene in an Iranian family with primary microcephaly. J Pak Med Assoc, 62, 1244-7.
  10. Hu RZ, Song FZ, Yuan CF, et al (2012). Effect of over-expression of BRIT1 gene on apoptosis of cervical cancer HeLa cells. Chin J Biologicals, 25, 429-32.
  11. Jo YH, Kim HO, Lee J, et al (2013). MCPH1 protein expression and polymorphisms are associated with risk of breast cancer. Gene, 517, 184-90.
  12. Liang Y, Gao H, Lin SY, et al (2010). MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet, 6, e1000826.
  13. Dan Longo, Anthony Fauci, Dennis Kasper, et al (2011). Harrison's Principles of Internal Medicine (18th ed). McGraw-Hill, New York, "Chapter 89".
  14. Driscoll M, Jackson AP, Jeggo PA (2006). Microcephalin,a causal linkbetween impaired damage response signalling and microcephaly. Cell Cycle, 5, 2339-44.
  15. Aldecott KW (2003). XRCC1 and DNA strand break repair. DNA Repair (Amst), 2, 955-69.
  16. Alderton GK, Galbiati L, Griffith E, et al (2006). Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nat Cell Biol, 8, 725-33, .
  17. Arthur TJ, Rachel IV, Stefan EP, et al (2012). Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol, 7, 42.
  18. Balmana J, Domchek SM, Tutt A, Garber JE (2011). Stumbling blocks on the path to personalized medicine in breast cancer, the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov, 1, 29-34.
  19. Basu B, Sandhu SK, de Bono JS (2012). PARP inhibitors, mechanism of action and their potential role in the prevention and treatment of cancer. Drugs, 72, 1579-90, .
  20. Bhattacharya N, Mukherjee N, Singh RK, et al (2012). Frequent Alterations of MCPH1 and ATM are Associated with Primary Breast Carcinoma, Clinical and Prognostic Implications. Ann Surg Oncol, 2, 12-45.
  21. Biesalski HK, Bueno de Mesquita B, Chesson A, et al (1998). European Consensus Statement on Lung Cancer, risk factors and prevention. Lung Cancer Panel. CA Cancer J Clin, 48, 167-76; discussion 164-6.
  22. Branzei D, Foiani M (2011). Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol, 11, 208-19.
  23. Bruning-Richardson A, Bond J, Alsiary R, et al (2011) ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer, 104, 1602-10.
  24. Cao JY, Liu L, Chen SP, et al (2010). Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer, 9, 237.
  25. Carter SL, Eklund AC, Kohane IS, et al (2006). A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet, 38, 1043-8.
  26. Chaplet M, Rai R, Jackson-Bernitsas D, et al (2006). BRIT1/MCPH1, a guardian of genome and an enemy of tumors. Cell Cycle, 5, 2579-83..
  27. Lin SY, Rai R, Li K, Xu ZX, Elledge SJ (2005). BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A, 102, 15105-9, .
  28. Lin SY, Rai R, Li K, et al (2005). BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1- Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A, 102, 15105-9.
  29. Lou Z, Minter-Dykhouse K, Wu X, Chen J (2003). MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature, 421, 957-61, .
  30. Lu C, Onn A, Vaporciyan AA, et al (2010). Holland-Frei Cancer Medicine (8th ed.). People's Medical Publishing House, Beijing, China, pp78.
  31. Mavrou A, Tsangaris GT, Roma E, Kolialexi A (2008). The ATM gene and ataxia telangiectasia. Anticancer Res, 28, 401-5.
  32. McCabe N, Turner N C, Lord C J, et al (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res, 66, 8109-15.
  33. Peng G, Yim EK, Dai H, et al (2009). BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat Cell Biol, 11, 865-72.
  34. Qin LX (2002). Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol, 8, 769-76.
  35. Rai R, Dai H, Multani AS, Li K, et al (2006). BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 10, 145-57.
  36. Rai R, Dai H, Multani AS, et al (2006). BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 10, 145-57.
  37. Richardson J, Shaaban AM, Kamal M, et al (2010). Reduced MCPH1 expression in breast cancer and response to chemotherapy. Breast Cancer Res, 12, p41.
  38. Richardson J, Shaaban AM, Kamal M, et al (2011).Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat, 127, 639-48.
  39. Roy R, Chun J, Powell SN (2011). BRCA1 and BRCA2, different roles in a common pathway of genome protection. Nat Rev Cancer, 12, 68-78.
  40. Shi L, Li M, Su B (2012). MCPH1/BRIT1 represses transcription of the human telomerase reverse transcriptase gene. Gene, 495, 1-9.
  41. Shi L, Li M, Lin Q, Qi X, Su B (2013). Functional divergence of the brain-size regulating gene MCPH1 during primate evolution and the origin of humans. BMC Biol, 11, 62.
  42. Stewart GS, Wang B, Bignell CR, et al (2003). MDC1 is a mediatorof the mammalian DNA damage checkpoint. Nature, 421, 961-6.
  43. Trimborn M, Schindler D, Neitzel H, Hirano T (2006). Misregulated chromosome condensation in MCPH1 primary microcephaly is mediated by condensin II. Cell Cycle, 5, 322-6.
  44. Van't Veer LJ, Dai H, van de Vijver MJ, et al (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6, .
  45. Venkatesh T, Nagashri MN, Swamy SS, et al (2013). Primary microcephaly gene MCPH1 shows signatures of tumor suppressors and is regulated by miR-27a in oral squamous cell carcinoma. PLoS One, 8, e54643.
  46. Vinay Kumar, Abul K Abbas, Nelson Fausto, et al (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier, Amsterdam, pp528-9.
  47. Xu X, Lee J, Stern DF (2004). Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J Biol Chem, 279, 34091-4.
  48. Yamashita D, Shintomi K, Ono T, et al (2011). MCPH1 regulates chromosome condensation and shaping as a composite modulator of condensin II. J Cell Biol, 194, 841-54.
  49. Yang SZ, Lin FT, Lin WC (2008). MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep, 9, 907-15.
  50. Zhang B, Wang E, Dai H, Hu R, et al (2013). BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis First published online, June 1.
  51. Zhou ZW, Tapias A, Bruhn C, et al (2013). DNA damage response in microcephaly development of MCPH1 mouse model. DNA Repair (Amst), 12, 645-55.

Cited by

  1. Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model vol.34, pp.33, 2015,
  2. Overexpression of MCPH1 inhibits uncontrolled cell growth by promoting cell apoptosis and arresting the cell cycle in S and G2/M phase in lung cancer cells vol.11, pp.1, 2015,